– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity and type 2 diabetes –
– Phase 1b data for CT-868, a once-daily injectable, dual GLP-1/GIP receptor agonist in development for the treatment of type 1 diabetes with overweight or obesity –
BERKELEY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) — Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people with metabolic diseases, today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany. Details regarding the clinical data presentations are as follows:
| Title: | CT-388, a once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in 4 weeks in overweight and obese adults |
| Authors: | M. Chakravarthy, F. Argüelles-Tello, A. Sun, M. Elliott, L. Acosta, J. Rankin, S. Hansen |
| Oral Session: | Activating two or three G’s; one of us is lonely |
| October 3 from 3:15 p.m. – 3:30 p.m. CEST | |
| Title: | Body weight independent effects of CT-868, a signaling biased dual GLP-1/GIP receptor modulator, on glucose homeostasis in overweight and obese adults with type 2 diabetes |
| Authors: | M. Hompesch, M. Elliott, M. Hernandez, S. Hansen, A. Macias, M. Chakravarthy |
| Oral Session: | Incretins and glucagon in action |
| October 4 from 12:00 p.m. – 12:15 p.m. CEST | |
Carmot’s pipeline includes:
About Carmot Therapeutics
Carmot is a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. Carmot’s expertise in metabolic biology has enabled the development of a broad pipeline of therapeutics, including three clinical candidates: CT-388 (once-weekly injectable, dual GLP-1/GIP receptor agonist), CT-868 (once-daily injectable, dual GLP-1/GIP receptor agonist) and CT-996 (once-daily oral, small molecule GLP-1 receptor agonist), and others in preclinical development. All of these are proprietary novel compounds, wholly-owned by Carmot, that have the potential to deliver an enhanced treatment response in people with metabolic diseases. For more information, visit the Carmot Therapeutics website and follow us on LinkedIn.
CONTACT: Carmot Contact: BD@carmot.us Carmot Media Contact: Kelli Perkins Red House Consulting kelli@redhousecomms.com
NASHVILLE, Tenn.--(BUSINESS WIRE)--#aesthetics--ObjectiveHealth, a Nashville-based integrated research and technology platform company, announced today that it…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leading AI-driven health technology company and portfolio company of nference, announced…
AI-powered clinical intelligence, seamless journey automation, and a robust network of behavioral health and medical…
Allele Capitals' Matt Hughes will moderate future forward panel on enterprise need in wearables for…
Recent expansion adds 7,500 square feet to the companies' headquarters LINDON, Utah, June 28, 2024…
Introducing SPINDLE, a pioneering robotic rehabilitation system to enhance daily living activities for individuals with…